{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T23:54:43Z","timestamp":1793922883408,"version":"4.8.0"},"reference-count":40,"publisher":"European Respiratory Society (ERS)","issue":"2","license":[{"start":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T00:00:00Z","timestamp":1730332800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["ERJ Open Res"],"accepted":{"date-parts":[[2024,10,6]]},"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Pulmonary hypertension (PH) associated with COPD (PH-COPD) exhibits diverse phenotypes, challenging therapeutic management. This study aimed to describe the characteristics of COPD patients with distinct phenotypes, namely end-stage COPD with or without PH (group 1), other COPD patients with mild-to-moderate pre-capillary PH-COPD (group 2) and COPD patients with a pulmonary vascular phenotype (PVP) (group 3).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We performed a retrospective analysis of COPD patients who underwent right heart catheterisation from 2015 to 2022.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>81 patients were included in group 1, 37 in group 2 and 35 in group 3. The groups differed in terms of clinical, functional, haemodynamic and imaging characteristics. Group 1 had significantly marked lung hyperinflation with increased total lung capacity and residual volume, a feature not observed in group 3. These results were confirmed by analysis of chest CT scans, which confirmed varying degrees of emphysema, as follows: severe in group 1, moderate in group 2 and mild in group 3, with median total emphysema indices of 55% (48\u201362), 32% (16\u201349) and 16% (3.4\u201331), respectively, p&lt;0.0001.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Our results highlight the broad spectrum of PH in COPD, from PH associated with end-stage COPD (phenotype\/group 1), characterised by predominant alveolar wall damage with severe emphysema, to PVP (phenotype\/group 3), mainly due to pulmonary vascular changes. Phenotype\/group 2 represents an intermediate state combining features of both. In the current debate on how to distinguish PH-COPD phenotypes, it might be of interest to include quantitative thresholds for emphysema in future diagnostic and management algorithms.<\/jats:p><\/jats:sec>","DOI":"10.1183\/23120541.00716-2024","type":"journal-article","created":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T17:15:23Z","timestamp":1730394923000},"page":"00716-2024","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Pulmonary hypertension associated with COPD: a phenotype analysis"],"prefix":"10.1183","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-4260-2042","authenticated-orcid":false,"given":"Mathilde","family":"Steger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8089-4846","authenticated-orcid":false,"given":"Matthieu","family":"Canuet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aissam","family":"Labani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8637-4593","authenticated-orcid":false,"given":"Jean Charles","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Enache","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armelle","family":"Schuller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e9o","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6056-202X","authenticated-orcid":false,"given":"Ari","family":"Chaouat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Kessler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9358-6922","authenticated-orcid":false,"given":"David","family":"Montani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6807-8582","authenticated-orcid":false,"given":"Marianne","family":"Riou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2024,10,31]]},"reference":[{"key":"2025032403450841000_11.2.00716-2024.1","unstructured":"Global Initiative for Obstructive Lung Disease . 2024 GOLD report. Date last accessed: 15 June 2024. Date last updated: 2024. https:\/\/goldcopd.org\/2024-gold-report\/"},{"key":"2025032403450841000_11.2.00716-2024.2","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/MCP.0000000000000890","article-title":"Emerging phenotypes of pulmonary hypertension associated with COPD: a field guide","volume":"28","author":"Garc\u00eda","year":"2022","journal-title":"Curr Opin Pulm Med"},{"key":"2025032403450841000_11.2.00716-2024.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2011.11.020"},{"key":"2025032403450841000_11.2.00716-2024.4","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00079512"},{"key":"2025032403450841000_11.2.00716-2024.5","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00944-2021"},{"key":"2025032403450841000_11.2.00716-2024.6","doi-asserted-by":"publisher","DOI":"10.1378\/chest.107.5.1193"},{"key":"2025032403450841000_11.2.00716-2024.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2022.01.031"},{"key":"2025032403450841000_11.2.00716-2024.8","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.159.1.9803117"},{"key":"2025032403450841000_11.2.00716-2024.9","doi-asserted-by":"publisher","DOI":"10.1378\/chest.127.5.1531"},{"key":"2025032403450841000_11.2.00716-2024.10","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.2107027"},{"key":"2025032403450841000_11.2.00716-2024.11","doi-asserted-by":"crossref","first-page":"2200879","DOI":"10.1183\/13993003.00879-2022","article-title":"2022 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"61","author":"Humbert","year":"2022","journal-title":"Eur Respir J"},{"key":"2025032403450841000_11.2.00716-2024.12","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200401-006OC"},{"key":"2025032403450841000_11.2.00716-2024.13","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.healun.2021.04.021","article-title":"Severe pulmonary hypertension associated with chronic obstructive pulmonary disease: a prospective French multicenter cohort","volume":"40","author":"Dauriat","year":"2021","journal-title":"J Heart Lung Transplant"},{"key":"2025032403450841000_11.2.00716-2024.14","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1164\/rccm.201801-0095PP","article-title":"Pulmonary vascular involvement in chronic obstructive pulmonary disease. Is there a pulmonary vascular phenotype?","volume":"198","author":"Kovacs","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"2025032403450841000_11.2.00716-2024.15","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S2213-2600(22)00097-2","article-title":"Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysis","volume":"10","author":"Hoeper","year":"2022","journal-title":"Lancet Respir Med"},{"key":"2025032403450841000_11.2.00716-2024.16","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1111\/resp.12772","article-title":"Pulmonary vasculature in COPD: the silent component","volume":"21","author":"Blanco","year":"2016","journal-title":"Respirology"},{"key":"2025032403450841000_11.2.00716-2024.17","doi-asserted-by":"publisher","DOI":"10.1046\/j.1469-7580.2002.00096.x"},{"key":"2025032403450841000_11.2.00716-2024.18","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.chest.2019.02.333","article-title":"Pulmonary arterial histologic lesions in patients with COPD with severe pulmonary hypertension","volume":"156","author":"Bunel","year":"2019","journal-title":"Chest"},{"key":"2025032403450841000_11.2.00716-2024.19","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.02.00245902"},{"key":"2025032403450841000_11.2.00716-2024.20","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01914-2018"},{"key":"2025032403450841000_11.2.00716-2024.21","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1159\/000441304","article-title":"Pulmonary arterial hypertension-specific drug therapy in COPD patients with severe pulmonary hypertension and mild-to-moderate airflow limitation","volume":"91","author":"Calcaianu","year":"2016","journal-title":"Respiration"},{"key":"2025032403450841000_11.2.00716-2024.22","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.healun.2016.04.010","article-title":"Sildenafil in severe pulmonary hypertension associated with chronic obstructive pulmonary disease: a randomized controlled multicenter clinical trial","volume":"36","author":"Vitulo","year":"2017","journal-title":"J Heart Lung Transplant"},{"key":"2025032403450841000_11.2.00716-2024.23","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02897-2021"},{"key":"2025032403450841000_11.2.00716-2024.24","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201402-0269PP"},{"key":"2025032403450841000_11.2.00716-2024.25","doi-asserted-by":"crossref","first-page":"107585","DOI":"10.1016\/j.rmed.2024.107585","article-title":"Survival and response to pulmonary vasodilator therapies in patients with chronic obstructive pulmonary disease and pulmonary vascular phenotype","volume":"225","author":"Steger","year":"2024","journal-title":"Respir Med"},{"key":"2025032403450841000_11.2.00716-2024.26","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.healun.2024.02.1044","article-title":"Compartment-specific remodeling patterns in end-stage chronic obstructive pulmonary disease with and without severe pulmonary hypertension","volume":"43","author":"Zeder","year":"2024","journal-title":"J Heart Lung Transplant"},{"key":"2025032403450841000_11.2.00716-2024.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2021.02.012"},{"key":"2025032403450841000_11.2.00716-2024.28","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.rmed.2015.05.022","article-title":"Lung function in pulmonary hypertension","volume":"109","author":"Low","year":"2015","journal-title":"Respir Med"},{"key":"2025032403450841000_11.2.00716-2024.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2021.07.005"},{"key":"2025032403450841000_11.2.00716-2024.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2011.08.035"},{"key":"2025032403450841000_11.2.00716-2024.31","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0173-2022"},{"key":"2025032403450841000_11.2.00716-2024.32","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1055\/s-0043-1770121","article-title":"Management of pulmonary hypertension associated with chronic lung disease","volume":"44","author":"Blanco","year":"2023","journal-title":"Semin Respir Crit Care Med"},{"key":"2025032403450841000_11.2.00716-2024.33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1203830"},{"key":"2025032403450841000_11.2.00716-2024.34","doi-asserted-by":"publisher","DOI":"10.1378\/chest.13-1422"},{"key":"2025032403450841000_11.2.00716-2024.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2014.08.009"},{"key":"2025032403450841000_11.2.00716-2024.36","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2015-207696"},{"key":"2025032403450841000_11.2.00716-2024.37","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201411-2120OC"},{"key":"2025032403450841000_11.2.00716-2024.38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa021322"},{"key":"2025032403450841000_11.2.00716-2024.39","first-page":"101008","article-title":"Hemodynamic characteristics in patients with pulmonary hypertension and chronic obstructive pulmonary disease: a retrospective monocentric cohort study","volume":"83","author":"Thor\u00e9","year":"2023","journal-title":"Respir Med Res"},{"key":"2025032403450841000_11.2.00716-2024.40","first-page":"101123","article-title":"Evidence and unresolved questions in pulmonary hypertension: insights from the 5th French Pulmonary Hypertension Network Meeting","volume":"86","author":"Boucly","year":"2024","journal-title":"Respir Med Res"}],"container-title":["ERJ Open Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/23120541.00716-2024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T11:31:28Z","timestamp":1742815888000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/23120541.00716-2024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,31]]},"references-count":40,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,3,24]]},"published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.1183\/23120541.00716-2024"],"URL":"https:\/\/doi.org\/10.1183\/23120541.00716-2024","relation":{},"ISSN":["2312-0541"],"issn-type":[{"value":"2312-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,31]]}}}